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dialysis patients.
Background. Hypertension may play an important role in the
pathogenesis of the excess cardiovascular and cerebrovascular
(CV) morbidity observed in hemodialysis patients (HD). How-
ever, the optimal blood pressure (BP) range for HD patients has
not been defined. We postulated that there is a “U” curve
relationship between BP and CV mortality. To explore this
hypothesis we studied 5,433 HD patients in Dialysis Clinic Inc., a
large not-for-profit chain, over a five year period.
Methods. Cox regression, with fixed and time-varying covariates,
was used to assess the effect of systolic blood pressure (SBP) and
diastolic blood pressure (DBP), pre- and post-dialysis, on CV
mortality, while adjusting for age, gender, ethnicity, primary cause
of end-stage renal disease, Kt/V, serum albumin, and antihyper-
tensive medications.
Results. The overall impact of BP on CV mortality was modest.
Pre-dialysis, neither systolic nor diastolic hypertension were asso-
ciated with an increase in CV mortality. Post-dialysis, SBP $ 180
mm Hg (RR 5 1.96, P , 0.015) and DBP $ 90 mm Hg (RR 5
1.73, P , 0.05) were associated with increased CV mortality. Low
SBP (SBP , 110 mm Hg) was associated with increased CV
mortality, pre- and post-dialysis.
Conclusions. The results suggest the presence of a “U” curve
relationship between SBP post-dialysis and CV mortality in HD
patients.
Hypertension is a leading public health problem in the
United States, affecting approximately 24% of the general
population [1, 2]. The detrimental effect of hypertension on
cardiovascular/cerebrovascular (CV) morbidity and mortal-
ity in the general population has been well established by
epidemiological studies [1, 3] and clinical trials [4–9].
Hypertension is also an important risk factor for declining
renal function [10, 11]. Lindeman, Tobin and Shock ob-
served a significant positive correlation between the rate of
decline in renal function and mean arterial pressure (MAP)
among hypertensive patients [10]. More recently, Klag et al
reported that hypertension is an important risk factor for
the development of end-stage renal disease (ESRD) [11].
Hypertension is present in 60 to 90% of hemodialysis
(HD) patients [12–15], and has been implicated in the
pathogenesis of the observed excess of CV morbidity and
mortality in these patients [16–20]. Foley et al reported
that in Caucasian HD patients, hypertension was associated
with echocardiographic evidence of an increased left ven-
tricular mass index and an increased risk for developing de
novo cardiac failure [16]. Charra et al attributed the
excellent survival that was observed in Tassin’s Centre de
Rein Artificiel to improved blood pressure (BP) control [17].
Iseki and Fukiyama recently reported an increase in the
cumulative incidence of stroke in Japanese HD patients
with hypertension [21]. Despite the association between
hypertension and increased left ventricular hypertrophy,
Foley et al also observed that low, not high, BP was
associated with increased mortality [16]. Other studies have
suggested that hypertension may not have a major adverse
effect on mortality of HD patients [22–24]. We recently
reported results of a preliminary study in HD patients in
which the best survival was associated with a systolic blood
pressure (SBP) of 150 to 179 mm Hg and a diastolic blood
pressure (DBP) of 90 to 99 mm Hg pre- and post-dialysis
[22]. Salem and Bower observed that in black HD patients
in the U.S., hypertension and the administration of antihy-
pertensive medications were associated with decreased
mortality [23]. Duranti, Imperiali and Sasdelli found that
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all-cause mortality and cardiovascular mortality were sim-
ilar in normotensive and hypertensive HD patients [24].
The disparate results of these studies may reflect differ-
ences in the ethnic composition of the small, homogenous
populations, as well as differences in research design,
analytic methods, serum albumin, and/or dialysis dose.
There has been considerable controversy regarding how
far blood pressure should be lowered to minimize mortality
[25–27]. Several observational studies in patients with
essential hypertension have described a “J” curve relation-
ship between treated DBP and CV mortality [28–31],
suggesting that low DBP may be associated with increased
CV mortality. Staessen et al [32] found a “U” shaped
relationship between treated SBP and all-cause mortality,
and an inverse relationship between treated DBP and
all-cause mortality in a randomized, double blind, placebo-
controlled trial in elderly hypertensive patients [32].
Among patients in the active treatment group, those who
had a SBP and/or DBP in the lowest third experienced the
greatest loss in body weight and had the highest mortality.
In contrast, among patients in the placebo group, those
whose treated DBP was in the middle third had the lowest
mortality [32].
We postulated that there may be a “J”- or “U”- curve
relationship between BP and mortality in HD patients. To
explore this hypothesis we assessed the association of SBP
and DBP, pre- and post-dialysis, with all-cause and CV
mortality over a period of five years in HD patients in
Dialysis Clinic, Inc. (DCI), a large, not-for-profit chain.
Our population demonstrated considerable ethnic diver-
sity, but was representative of the U.S. HD population with
respect to age, serum albumin, dialysis dose, BP control
and cause of ESRD at the time of the study [3, 33].
METHODS
Patients
We studied 5,433 HD patients dialyzed in freestanding
units operated by Dialysis Clinic, Inc. (DCI). Patient data
were obtained from a computerized medical information
system. The study period was from January 1, 1992 through
December 31, 1996. Inclusion criteria included (1) patients
already being dialyzed as of January 1, 1992 (prevalent)
(N 5 2,130), or patients who began dialysis between January
1, 1992 and September 30, 1994 (N 5 3,303); (2) survival of 90
days or more since first HD in a DCI facility; (3) regularly
scheduled dialysis, three times a week in an out-patient
facility. Patients who had a kidney transplant prior to entry
into the study were excluded. Because some patients initiated
HD treatment prior to entry into the study, time since the
first HD treatment was also included as a covariate in the
analyses. Patients were followed for up to 46 months and
censored at time of transplant or loss to follow-up.
Covariates
Information was obtained for the following covariates:
age, ethnicity, gender, years on dialysis prior to entry into
the study, primary cause of ESRD, blood pressure, hemat-
ocrit, serum albumin, dialysis dose (Kt/V), erythropoietin
(EPO) dose, inter-dialytic weight gain, and use of antihy-
pertensive medications. For each patient, the first valid
laboratory value for the calendar quarter was used. If the
value for a specific calendar quarter was missing it was
replaced with the value from the previous quarter. Approx-
imately 5% of the BP values for any individual were
missing. Single pool Kt/V was calculated according to the
method described by Daugirdas [34]. Kt/V and serum
albumin were treated as time-dependent covariates in all
analyses. The use of antihypertensive medications was
treated as a fixed dichotomous covariate in all analyses.
Patients were coded as receiving antihypertensive medica-
tions if at any time during the study period they were taking
any antihypertensive medications.
Blood pressure (BP). Systolic blood pressure (SBP) and
diastolic blood pressure (DBP) were measured with the
patient in a sitting position, pre- and post-dialysis, by
trained healthcare professionals. Phases I and V of the
Korotkoff sounds were used to determine SBP and DBP,
respectively. For patients initially included in the study on
January 1, 1992, baseline values for SBP and DBP were the
calculated averages SBP and DBP, pre- and post-dialysis,
over the first 90 days in 1992. For patients coming into the
study later, baseline values for both SBP, DBP, and mean
arterial pressure (MAP), pre- and post-dialysis, were aver-
aged over the first 90 days after beginning dialysis in DCI
facilities. When BP was analyzed as a time-varying covari-
ate, values for SBP, DBP, and MAP, respectively, were
averaged over a calender quarter and used to predict
survival in the following quarter. SBP (,110 to $180 mm
Hg) and DBP (,70 to $90) were categorized in 10 mm Hg
increments. MAP was categorized into quintiles, with the
highest quintile chosen as the reference category.
Deaths. Date and cause of death were obtained from
HCFA Death Notification forms (2746) and coded using
the International Classification of Disease, 9th revision
(ICD-9). Deaths were classified as cardiovascular/cerebro-
vascular-related (CV) or non-CV related. CV-related
deaths included hypertensive disease (ICD-9 401-405),
ischemic heart disease (IDC-9 410-414), other heart disease
(IDC-9 420-429), and cerebrovascular disease (ICD-9 430-
438). Death due to any other cause was coded as a
non-CV-related death.
Statistical analysis
The principal outcomes in this study were CV and
all-cause mortality. Patients were followed until death,
transplant, last dialysis at a DCI clinic, or December 31,
1996, whichever was earliest. The effects of SBP, DBP, and
MAP, both pre- and post-dialysis, on death rates were
analyzed using univariate and multivariate Cox propor-
tional hazards models. The multivariate models adjusted
for demographic covariates, serum albumin, Kt/V, primary
cause of ESRD, and antihypertensive medications. Blood
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pressure, serum albumin, and Kt/V were treated as time-
dependent covariates.
Survival analyses were performed in two steps. In the first
step, models were constructed using BP as a fixed covariate
measured at baseline. Baseline BP was estimated by calcu-
lating the average of all BP measurements during the first
90 days of HD in DCI. In the second step, SBP, DBP, and
MAP were treated as time-dependent covariates (see be-
low). The effects of BP pre- and post-dialysis were exam-
ined in separate models.
We also examined the possibility of non-additive effects
of SBP and DBP on mortality. BP categories were adapted
from the categorizations used by Klag et al [11] and by the
Fifth Joint National Committee Report on Detection,
Evaluation, and Treatment of High Blood Pressure (JNC
V) [2]. The categories were (1) optimal: SBP , 120 mm Hg
and DBP , 80 mm Hg; (2) normal, not optimal: SBP 120
to 129 mm Hg and DBP , 84 mm Hg or DBP 80 to 84 mm
Hg and SBP , 130 mm Hg; (3) high normal: SBP 130 to
139 mm Hg and DBP , 90 mm Hg, or DBP 85 to 89 mm
Hg and SBP , 140 mm Hg; (4) mild hypertension: SBP 140
to 159 mm Hg and DBP , 100 mm Hg or DBP 90 to 99 mm
Hg and SBP , 160 mm Hg; (5) moderate hypertension:
SBP 160 to 179 mm Hg and DBP , 110 mm Hg or DBP
100 to 109 mm Hg and SBP , 180 mm Hg; and (6)
severe/very severe hypertension: SBP $ 180 mm Hg or
DBP $ 110 mm Hg.
Time-dependent covariate values were based on quar-
terly measurements, and separate categories were created
for those missing any of the quarterly laboratory values.
When a value for a specific quarter was missing it was
replaced with the value from the previous quarter. When
values for two or more sequential quarters were missing, all
but the first value were coded as missing. The proportion-
ality assumption of the Cox model was evaluated using
plots of the hazard function, stratification, and introduction
of time-dependent covariates. Cause-specific mortality was
analyzed in a similar fashion. Statistical analyses were
performed using the PHREG procedure of SAS [35].
RESULTS
The demographic characteristics and the laboratory val-
ues of the study population at the time of entry into the
study are shown in Table 1. The mean age was 59 6 15.5
(SD). There were approximately equal numbers of females
and males, and African descent (black) and European
descent (white)/Hispanic ethnicities, respectively. The pri-
mary causes of ESRD were diabetes mellitus (33.1%),
hypertension (32.4%), and glomerulonephritis/other
(34.5%). The majority of patients (64.6%) received antihy-
pertensive medication sometime during the study. Preva-
lent patients were on dialysis for a mean of 1.75 6 2.9 years
prior to entry into the study. Serum albumin and Kt/V
levels were approximately normally distributed. Mean se-
rum albumin was 3.7 6 0.5 g/dl. The percentile values for
serum albumin (g/dl) were 4.3 (95th), 4.0 (75th), 3.7 (50th),
3.4 (25th), and 2.8 (5th), respectively. Mean Kt/V was 1.1 6
0.3. The percentile values for Kt/V were 1.67 (95th), 1.30
(75th), 1.10 (50th), 0.92 (25th), and 0.66 (5th), respectively.
Mean inter-dialytic weight gain was 2.5 6 0.93 kg. Mean
hematocrit was 28.2 6 4.6%. The percentile values for
hematocrit (%) were 35.8 (95th), 31.0(75th), 28.2 (50th), 25.1
(25th), and 21.0 (5th). The mean EPO dose was 3, 581 6
1,467 units, intravenously, after each dialysis treatment.
The percentile values for EPO dosage (units) were 6,087
(95th), 4,224 (75th), 3,486 (50th), 2,500 (25th), and 1,513
(5th). The duration of observation was 13,984 patient years
and mean follow-up per patient was 2.6 6 1.5 years. We
observed 2,281 deaths (42%) during the study.
Values for covariates in different blood pressure strata
The values (mean 6 SD) for Kt/V, albumin, hematocrit,
EPO dose and inter-dialytic weight gain for each of the SBP
and DBP categories are shown in Table 2. At baseline,
there were no significant correlations between EPO dosage
and either SBP or DBP pre-dialysis. However, there were
small, but statistically significant, inverse correlations be-
tween hematocrit and both SBP pre-dialysis (r 5 20.06,
P , 0.001) and DBP pre-dialysis (r 5 20.06, P , 0.001).
There were also small, but statistically significant, inverse
correlations between Kt/V and SBP pre-dialysis (r 5 20.07,
P , 0.001) and DBP-pre-dialysis (r 5 20.11 P , 0.001).
Inter-dialytic weight gain was positively correlated with
both SBP pre-dialysis (r 5 0.14, P , 0.001) and DBP
pre-dialysis (r 5 0.21, P , 0.001).
Table 1. Hemodialysis patient characteristics at baselinea: 1992–1996
(N 5 5433)
Variable
Mean (SD) or
percent
Demographics
Mean age, years (SD) 58.9 (15.5)
Years on dialysis prior to entry into study 1.7 (2.9)
Race % Black 48.5
Gender % female 51.0
Cause of ESRD
Diabetes % 33.1
Hypertension % 32.4
Glomerulonephritis/Other % 34.5
Antihypertensive medication, % yes 64.6
Pre-dialysis blood pressure, mean (SD)
Systolic mm Hg 150.9 (18.0)
Diastolic mm Hg 79.8 (10.3)
Mean arterial blood pressure mm Hg 103.4 (11.6)
Post-dialysis blood pressure, mean (SD)
Systolic mm Hg 139.5 (17.1)
Diastolic mm Hg 75.8 (9.2)
Mean arterial blood pressure mm Hg 97.1 (10.6)
Albumin g/dl 3.7 (0.5)
Kt/V 1.1 (0.3)
Inter-dialytic weight gain kg 2.4 (0.9)
Hematocrit % 28.2 (4.6)
Erythropoietin dose per treatment 3,581 (1,467)
Abbreviation is ESRD, end-stage renal disease.
a At the time of entry into the study.
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Age-adjusted relative death rates
Age-adjusted relative death rates are shown in Table 3.
Variables significantly associated with increased, age-ad-
justed death rates included white/Hispanic ethnicity, diabe-
tes mellitus as primary cause of ESRD, hypoalbuminemia,
Kt/V , 1.10, and not using antihypertensive medications.
Years on dialysis prior to coming to DCI was not associated
with a significant increase in mortality. After age adjust-
ment, the overall effect of baseline BP on all-cause mor-
tality was modest. Low baseline BP rather than high BP was
related to increased mortality.
Multivariate analyses
SBP and DBP, pre-dialysis. Table 4 shows a comparison
of the relative death rate (RR) when SBP pre-dialysis
(SBP-pre) and DBP pre-dialysis (DBP-pre) were analyzed
as fixed covariates at baseline (Model A) and as time-
dependent covariates (Model B). Both models adjust for
the following covariates: age, race, gender, cause of ESRD,
Table 2. Baseline laboratory values (mean, SD) for hemodialysis patients by blood pressure categories
Kt/V Albumin Hematocrit Weight gain Epogen
SBP-pre
,110 1.18 (0.40) 3.50 (0.52) 29.36 (4.95) 2.27 (0.99) 3276.61 (1589.73)
110–19 1.14 (0.31) 3.63 (0.48) 28.43 (4.50) 2.33 (1.05) 3680.63 (1506.22)
120–29 1.22 (0.36) 3.69 (0.44) 28.51 (4.70) 2.16 (0.83) 3726.93 (1526.97)
130–39 1.13 (0.33) 3.64 (0.48) 28.47 (4.57) 2.34 (0.93) 3605.41 (1551.99)
140–49 1.13 (0.33) 3.65 (0.49) 28.29 (4.67) 2.39 (0.89) 3549.36 (1437.96)
150–59 1.12 (0.33) 3.66 (0.48) 28.11 (4.44) 2.49 (0.90) 3598.06 (1426.53)
160–69 1.11 (0.34) 3.69 (0.45) 27.74 (4.39) 2.56 (0.95) 3549.00 (1447.31)
170–79 1.12 (0.34) 3.65 (0.45) 28.11 (4.56) 2.65 (0.97) 3561.14 (1445.46)
1801 1.07 (0.29) 3.70 (0.48) 27.81 (4.84) 2.72 (0.94) 3570.39 (1510.51)
DBP-pre
,70 1.17 (0.34) 3.55 (0.44) 28.43 (4.20) 2.23 (0.87) 3725.55 (1464.22)
70–79 1.15 (0.34) 3.64 (0.46) 28.34 (4.26) 2.34 (0.88) 3557.47 (1439.45)
80–89 1.11 (0.32) 3.71 (0.47) 28.06 (4.84) 2.53 (0.92) 3514.48 (1459.74)
901 1.06 (0.33) 3.72 (0.51) 27.79 (4.96) 2.82 (1.00) 3629.25 (1536.92)
Table 3. Age-adjusted relative death rates for hemodialysis patients:
1992–1996 (N 5 5433)
Variables RR 95% CI
Gender (female vs. male) 0.95 (0.88–1.04)
Ethnicity (black vs. white/Hispanic) 0.62f (0.57–0.67)
Years on dialysis prior to study start
(per 10 years)
0.99 (0.97–1.00)
Primary cause of ESRDa
Diabetes 1.22g (1.11–1.35)
Hypertension 0.87g (0.78–0.96)
Antihypertensive medication (yes) 0.72f (0.67–0.79)
BP baselineb pre-dialysis (per 10 mm
Hg increase)
Systolic BP 0.93f (0.91–0.95)
Diastolic BP 0.84f (0.80–0.89)
MAP 0.86f (0.82–0.90)
BP baseline post-dialysis (per 10 mm
Hg increase)
Systolic BP 0.97h (0.95–1.00)
Diastolic BP 0.85f (0.80–0.90)
MAP 0.90f (0.86–0.95)
Albuminc,d g/dl
,3.0 6.70f (5.86–7.66)
3.0–3.4 2.38f (2.15–2.63)
3.5–3.9 1.00 —
4.0 or . 0.61f (0.54–0.70)
Missing 2.35f (1.96–2.81)
Kt/Vc,e
,1.10 1.36f (1.20–1.55)
1.10–1.31 1.07 (0.95–1.21)
1.32–1.49 0.96 (0.84–1.09)
Missing 1.58f (1.34–1.86)
Abbreviations are: RR, relative death rate; CI, confidence interval;
ESRD, end-stage renal disease; MAP, mean arterial blood pressure.
a Glomerulonephritis/other is the reference category
b At the time of entry into the study
c Treated as a time-varying covariate
d Albumin value of 3.5–3.9 is the reference category
e Kt/V value of 1.51 is the reference category
f P , 0.001
g P , 0.01
h P , 0.05
Table 4. Comparison of relative death ratesa (RR) and 95% confidence
interval (CI) for baselineb SBP pre-dialysis and DBP pre-dialysis
(Model A), and as time-varying covariates (Model B)
Covariate
Model A Model B
N RRa 95% CI RRa 95% CI
SBP-pre
,110 93 1.64c (1.22–2.20) 3.07c (2.50–3.76)
110–19 196 1.18 (0.93–1.50) 2.27c (1.89–2.75)
120–29 356 1.19 (0.99–1.43) 1.43c (1.20–1.71)
130–39 734 1.08 (0.94–1.25) 1.14 (0.98–1.33)
140–49 1127 1.00 — 1.00 —
150–59 1248 0.97 (0.85–1.10) 0.73d (0.63–0.85)
160–69 944 1.02 (0.88–1.17) 0.56c (0.47–0.66)
170–79 493 0.86 (0.72–1.03) 0.58c (0.46–0.72)
1801 242 0.90 (0.71–1.15) 0.77 (0.60–0.99)
DBP-pre
,70 846 0.96 (0.84–1.09) 1.06 (0.93–1.21)
70–79 2034 1.00 — 1.00 —
80–89 1668 1.03 (0.92–1.16) 0.91 (0.78–1.05)
901 885 1.10 (0.92–1.32) 1.23 (1.00–1.51)
Abbreviations are: RR, relative death rate; CI, confidence interval;
ESRD, end-stage renal disease; SBP-pre, systolic blood pressure pre-
dialysis; DBP-pre, diastolic blood pressure pre-dialysis.
a Adjusted for age, race, gender, cause of ESRD, Kt/V, serum albumin,
antihypertensive medication
b At the time of entry into the study
c P 5 0.001
d P , 0.01
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Kt/V, serum albumin, and use of antihypertensive medica-
tions. In model A, patients with SBP pre-dialysis ,110 mm
Hg had a 64% increased death rate (RR 5 1.64, P 5 0.001)
compared with the reference category (SBP pre-dialysis
140 to 149 mm Hg). In model B, the RR for death was
threefold higher for patients with SBP pre-dialysis ,110
mm Hg (RR 5 3.07, P 5 0.001). The association of
increased mortality with low SBP was present in patients
both receiving and not receiving antihypertensive medica-
tions, and for the group as a whole (results not shown).
SBP and DBP, post-dialysis. Table 5 presents the com-
parison of the RR of death when SBP post-dialysis (SBP-
post) and DBP post-dialysis (DBP-post) were entered into
the model, first as fixed covariates (Model A) and later as
time-dependent covariates (Model B). In model A, patients
with DBP post-dialysis ,70 mm Hg had a 16% increased
death rate (RR 5 1.16, P , 0.05) compared with the
reference category (70 to 79 mm Hg). In model B, the RR
was highest for patients with SBP post-dialysis ,110 mm
Hg (RR 5 2.04, P 5 0.001) and those with SBP post-
dialysis of $180 mm Hg (RR 5 1.73, P 5 0.001). SBP
post-dialysis was a better predictor of mortality when
analyzed as a time-varying covariate compared with using
only the baseline value.
Non-additive effects of BP. The effects of baseline, pre-
dialysis BP on mortality are shown in Table 6. In this model
we assumed that the effects of SBP and DBP are not
additive and therefore SBP and DBP are considered
jointly. Patients with mild (22%) and moderate (22%)
hypertension both had a reduced risk of death compared
with patients with optimal BP (SBP , 120 mm Hg and
DBP , 80 mm Hg) after controlling for the covariates.
Cause-specific mortality for time-varying SBP and DBP,
pre-dialysis. Patients with SBP pre-dialysis ,110 mm Hg
had a fourfold increase in RR of cardiac-related death
versus patients with SBP pre-dialysis 140 to 149 mm Hg
(Table 7). Moreover, patients with SBP pre-dialysis .150
mm Hg had a decreased risk of cardiac-related death
compared with the reference BP group (140 to 149 mm
Hg). A similar pattern was observed among patients who
Table 5. Comparison of relative death ratea (RR) and 95% confidence
interval (CI) for baselineb SBP post-dialysis and DBP post-dialysis
(Model A), and as time-varying covariates (Model B)
Covariate
Model A Model B
N RRa 95% CI RRa 95% CI
SBP-post
,110 209 1.02 (0.81–1.29) 2.04c (1.70–2.45)
110–19 450 0.90 (0.75–1.09) 1.37c (1.16–1.63)
120–29 908 0.96 (0.85–1.14) 1.08 (0.92–1.26)
130–39 1211 0.99 (0.88–1.13) 1.02 (0.88–1.18)
140–49 1212 1.00 — 1.00 —
150–59 842 0.97 (0.84–1.12) 0.89 (0.75–1.06)
160–69 402 1.07 (0.89–1.28) 0.97 (0.78–1.20)
170–79 152 1.11 (0.85–1.46) 1.17 (0.87–1.58)
1801 47 0.87 (0.53–1.43) 1.73c (1.19–2.50)
DBP-post
,70 1396 1.14d (1.02–1.27) 1.10 (0.95–1.27)
70–79 2402 1.00 — 1.00 —
80–89 1269 1.06 (0.93–1.20) 0.99 (0.83–1.18)
901 366 0.94 (0.73–1.22) 1.24 (0.90–1.70)
Abbreviations are: RR, relative death rate; CI, confidence interval;
ESRD, end-stage renal disease; SBP-post, systolic blood pressure post-
dialysis; DBP-post, diastolic blood pressure post-dialysis.
a Adjusted for age, race, gender, cause of ESRD, Kt/V, serum albumin,
antihypertensive medication
b At the time of entry into the study
c P 5 0.001
d P , 0.05
Table 6. Non-additive effects of baselinea blood pressure pre-dialysis
on survival in hemodialysis patients (N 5 5433)
Blood pressure categoryb N RRc 95% CI
Optimal 287 1.00 —
Normal, not optimal 350 0.92 (0.74–1.14)
High normal 728 0.85 (0.70–1.02)
Mild hypertension 2368 0.78d (0.66–0.93)
Moderate hypertension 1452 0.78d (0.65–0.94)
Severe/very severe hypertension 248 0.75e (0.58–0.97)
Abbreviations are: RR, relative death rate; CI, confidence interval;
SBP, systolic blood pressure; DBP, diastolic blood pressure.
a At the time of entry into the study
b Blood pressure categories are: (1) optimal: SBP , 120 mm Hg and
DBP , 80 mm Hg; (2) normal, not optimal: SBP 120–129 mm Hg and
DBP , 84 mm Hg or DBP 80–84 mm Hg and SBP , 130 mm Hg; (3) high
normal: SBP 130–139 mm Hg and DBP , 90 mm Hg or DBP 85–89 mm
Hg and SBP , 140 mm Hg; (4) mild hypertension: SBP 140–159 mm Hg
and DBP , 100 mm Hg or DBP 90–99 mm Hg and SBP , 160 mm Hg;
(5) moderate hypertension: SBP 160–179 mm Hg and DBP , 110 mm Hg
or DBP 100–109 mm Hg and SBP , 180 mm Hg; (6) severe/very severe
hypertension: SBP $ 180 mm Hg and/or DBP $ 110 mm Hg. Optimal is
the reference category.
c Adjusted for age, race, gender, cause of ESRD, Kt/V, serum albumin,
antihypertensive medication.
d P , 0.01
e P , 0.06
Table 7. Cause-specific relative death ratea (RR) and 95% confidence
interval (CI) for SBP and DBP pre-dialysis as time-varying covariates
Covariate
Cardiac-related cause
of death
Non-cardiac-related
cause of death
RRa 95% CI RRa 95% CI
SBP-pre
,110 3.95b (2.97–5.26) 2.37b (1.77–3.16)
110–19 2.68b (2.03–3.53) 1.91b (1.46–2.51)
120–29 1.86b (1.46–2.37) 1.08 (0.83–1.40)
130–39 1.18 (0.94–1.48) 1.10 (0.89–1.37)
140–49 1.00 — 1.00 —
150–59 0.79c (0.63–0.97) 0.68c (0.55–0.85)
160–69 0.56b (0.43–0.71) 0.56 (0.43–0.72)
170–79 0.54c (0.40–0.74) 0.61 (0.45–0.84)
1801 0.72 (0.50–1.02) 0.83 (0.58–1.19)
DBP-pre
,70 1.00 (0.84–1.20) 1.12 (0.93–1.34)
70–79 1.00 — 1.00 —
80–89 0.96 (0.80–1.17) 0.87 (0.71–1.05)
901 1.43c (1.08–1.91) 1.05 (0.78–1.41)
a Adjusted for age, race, gender, cause of ESRD, Kt/V, serum albumin,
and antihypertensive medication
b P , 0.001
c P , 0.05
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died of non-cardiac-related conditions, although the mag-
nitude of the BP effect was smaller.
Cause-specific mortality for time-varying SBP and DBP,
post-dialysis. Patients with SBP post-dialysis ,110 mm Hg
had a 2.8-fold increase in RR for a cardiac-related death
compared with patients with SBP post-dialysis 140 to 149
mm Hg (Table 8). Mortality risk was also increased for
patients with SBP post-dialysis $180 mm Hg (RR 5 1.96,
P , 0.01). These data are consistent with a “U”-curve
relationship between SBP post-dialysis and cardiac-related
mortality (Fig. 1). A J-shape pattern was observed for DBP
post-dialysis and cardiac-related mortality. Patients with a
DBP post-dialysis $90 mm Hg had a 73% increased RR for
cardiac-related death versus patients with DBP post-dialy-
sis of 70 to 79 mm Hg. Among patients who died of a
non-cardiac-related condition, the RR of death was highest
among those with a SBP post-dialysis ,110 mm Hg, (RR 5
1.55, P , 0.01) and those with SBP post-dialysis $180 mm
Hg (RR 5 1.48, NS).
DISCUSSION
We found the overall impact of BP on both all-cause and
CV mortality to be modest. Low SBP, both pre-dialysis and
post-dialysis, when treated as fixed or time-varying covari-
ates, was associated with increased CV and non-CV mor-
tality. Pre-dialysis systolic hypertension was not associated
with an increase in either CV or non-CV mortality. How-
ever, post-dialysis hypertension with SBP $ 180 mm Hg
and DBP $ 90 mm Hg, when the values were treated as
time-varying covariates, was associated with significant
increases in CV mortality.
Although the results obtained in the two Cox models A
and B (fixed and time-varying) were similar (Table 5),
model A did not predict an increase in mortality for
patients with a post-dialysis SBP $ 180 mm Hg or SBP ,
110 mm Hg. In contrast, model B predicted increased
mortality for both groups. Models utilizing fixed covariates
are easier to construct and analyze. However, because
certain covariates, such as BP, serum albumin, and Kt/V
may change over the study period, the models that incor-
porate time-varying covariates are likely to be more accu-
rate in predicting mortality. These models do have a
potential problem, however, in that changes in the values of
specific covariates may be a response to, rather than a cause
of, changes in the underlying disease process. To minimize
this possibility values of time-varying covariates were
lagged by one quarter: we used the values from the
previous quarter to predict death in the next quarter. Based
on post-hoc analyses, the percentage BP values missing for
any quarter for a patient included in the study was approx-
imately 5%. Administration of antihypertensive medica-
tions was associated with decreased age-adjusted mortality.
Our study population was similar to the U.S. hemodial-
ysis population with respect to age and gender [36], serum
albumin, Kt/V, urea reduction ratio (URR), and preva-
lence of diabetes (Table 9). Our study was also similar with
respect to blood pressure control (Table 10). However, our
study contained a slightly higher proportion of African
Americans (48.5%) than the U.S. HD population (40%)
[36].
The prevalence of hypertension in our study (64%) was
Fig. 1. Systolic blood pressure post-dialysis (SBP; time-varying) and
cardio/cerebrovascular mortality in hemodialysis (HD) patients 1992 to
1996. The “U” curve relationship between SBP post-dialysis and mortality
is: SBP , 110 mm Hg, RR 5 2.62, **P , 0.01 versus reference 140 to 49;
SBP 110 to 19 mm Hg, RR 5 1.48, **P , 0.01 versus reference; SBP $
180 mm Hg, RR 5 1.06, *P , 0.05 versus reference.
Table 8. Cause-specific relative death ratea (RR) and 95% confidence
interval (CI) for SBP and DBP post-dialysis as time-varying covariates
Covariate
Cardiac-related cause
of death
Non-cardiac related
cause of death
RRa 95% CI RRa 95% CI
SBP-post
,110 2.62b (2.04–3.35) 1.55c (1.18–2.03)
110–19 1.48b (1.16–1.89) 1.27 (1.00–1.62)
120–29 1.04 (0.84–1.30) 1.11 (0.89–1.38)
130–39 1.06 (0.86–1.30) 0.98 (0.79–1.21)
140–49 1.00 — 1.00 —
150–59 0.98 (0.77–1.24) 0.80 (0.62–1.03)
160–69 0.87 (0.64–1.18) 1.08 (0.81–1.45)
170–79 1.27 (0.85–1.89) 1.08 (0.70–1.68)
1801 1.96c (1.20–3.19) 1.48 (0.84–2.60)
DBP-post
,70 1.04 (0.84–1.28) 1.15 (0.95–1.40)
70–79 1.00 — 1.00 —
80–89 0.97 (0.75–1.26) 1.01 (0.79–1.28)
901 1.73d (1.14–2.62) 0.84 (0.50–1.40)
a Adjusted for age, race, gender, cause of ESRD, Kt/V, serum albumin,
and anti-hypertensive medication.
b P , 0.001
c P , 0.01
d P , 0.05
Table 9. Characteristics of patients in the DCI Blood Pressure Study
Serum albumin Kt/V URR % % Diabetic
DCI 3.7 g/dl 1.23 63.3 33
U.S. 3.8 g/dla 1.21b 63.2b 37a
a ESRD Core Indicator Project 1996 [12]
b Dialysis Morbidity and Mortality Study (DMMS) Wave I patients:
USRDS 1996 Annual Report, Bethesda, National Institutes of Health,
April 1996 [41]
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higher than that recently reported by Foley et al [16], and
Charra et al [17]. These small study populations differ from
the current U.S. ESRD population with respect to age,
ethnicity, and prevalence of diabetes. The demographic
profile of the ESRD population has changed significantly
over the last 10 to 15 years. Patients are now older and have
more comorbidities, including diabetes and CV disease
[37]. The majority of studies that have reported on low
rates of hypertension and are cited in the literature were
conducted almost 30 years ago. For example, the preva-
lence of hypertension reported by Stokes et al in 1970 and
Vertes et al in 1969 was 10 to 15% [13, 38]. The prevalence
of systolic hypertension (SBP . 150 mm Hg) in DCI in
quarter four of 1995, pre-dialysis 54% and post-dialysis
16%, was similar to that observed in the ESRD Core
Indicators Project pre-dialysis 53% and post-dialysis 17%
[12].
Low levels of serum albumin [39] and Kt/V [40] are
detrimental for survival of ESRD patients. Although the
mean serum albumin and delivered dose of Kt/V were
lower in our study population than the current DOQI
recommendations, they were similar to those of the U.S.
HD population during the study period [41]. The mean
dose of delivered Kt/V in the DCI study clinics increased
from 1.15 in quarter four of 1992 to 1.45 in quarter four of
1996. A similar trend was reported in the 1996 USRDS
Annual Data Report for ESRD patients who had been on
dialysis for more than one year [41].
The results of our study are consistent with those of other
reports that were unable to demonstrate a significant linear
relationship between elevated BP and increased mortality
in HD patients [16, 23, 33]. The study by Foley et al recently
reported that each 10 mm Hg increase in MAP, averaged
from monthly values over the duration of dialysis, was
associated with increased relative risk for the development
of left ventricular hypertrophy (sevenfold) and de novo
cardiac failure (twofold). These researchers also demon-
strated that a low, not high, MAP was associated with
increased CV mortality and antecedent cardiac failure,
possibly caused by pre-existing hypertension [16]. The
association between increased CV mortality and low SBP
observed in our study was statistically significant after
controlling for the effects of age, gender, ethnicity, primary
cause of ESRD, antihypertensive medications, and dialysis
dose.
A 1992 report by Charra et al attributed the excellent
long-term survival observed in the Centre de Rein Artificiel
in Tassin to normalization of BP [17]. Although this report
contrasts with our findings, there are several important
differences in study design between the Tassin study and
our own. Our study population was significantly larger and
more diverse than that of the Tassin study, and weekly time
on dialysis and Kt/V were significantly higher in the Tassin
study. It is possible that the beneficial effect of BP control
on survival may require a threshold dose of dialysis. Our
study showed a modest, but statistically significant, inverse
correlation between Kt/V and BP. Despite this association
we were unable to demonstrate a significant decrease in
mortality associated with Kt/V . 1.1 compared with a
Kt/V 5 1.1 after controlling for age, serum albumin, and
other covariates. With a follow-up period of 20 years,
compared with five years in our study, the Tassin study had
a longer period of observation to demonstrate a significant
impact of BP on mortality. However, the fact that 42% of
our patients died during the study period indicates that we
had adequate power to detect an association between blood
pressure and mortality.
The presence of significant positive correlations between
inter-dialytic weight gain and pre-dialysis BP indicates that
occult volume overload may have contributed to the post-
dialysis hypertension observed in our study. Therefore, the
association between inter-dialytic weight gain, BP, and
mortality was tested by post-hoc analyses. When inter-
dialytic weight gain (a time-varying covariate) was added to
the model, large inter-dialytic weight gains (.4 kg) did not
have a significant adverse effect on mortality.
These results suggest that there is a small segment of HD
patients who remain severely hypertensive despite HD and
BP treatment, and that post-dialysis hypertension is asso-
ciated with an increased risk for CV mortality.
Iseki and Fukiyama observed an increased incidence of
stroke associated with progressive increases in both SBP
and DBP in Japanese HD patients [21]. Although SBP and
DBP tended to be higher in patients who experienced a
stroke versus those who did not, the absolute differences
were modest. Moreover, compared with patients without a
stroke, the stroke patients were older, had been on dialysis
longer, and were more likely to be diabetics and smokers.
Ferna´ndez et al reported significant increases in morbid-
ity and mortality in HD patients with an average pre-
dialysis MAP . 115 mm [18]. However, several factors may
contribute to the differences between that report and our
findings: the Ferna´ndez et al study population was small
(N 5 104), predominately male (62.5%), and contained
only eight diabetics; the majority of patients were dialyzed
with cuprophane membranes and acetate dialysate; and the
investigators did not examine the effect of antihypertensive
medications.
The impact of antihypertensive drugs on mortality in our
study is difficult to assess. As a group, patients who received
antihypertensive agents had a decreased risk for mortality
Table 10. Comparison of blood pressure values in DCI and U.S.
hemodialysis patients
SBP-pre SBP-post DBP-pre DBP-post
mean
%
.150 Mean-post
%
.150 Mean
%
.90 Mean
%
.90
DCI 153.9 53.5 136.8 26.4 80.7 16.0 74.6 6.6
U.S. 152.0 53.0 139.0 27.0 79.0 17.0 74.0 7.0a
a U.S. data are from the 1996 ESRD Core Indicator Project [12].
Zager et al: Blood pressure and cerebrovascular morbidity 567
compared with those not receiving antihypertensive ther-
apy. This relationship remained statistically significant even
after adjusting for BP. Recently, Salem and Bower reported
a similar observation, in a small, but demographically
comparable, population [23]. We recognize that some
antihypertensive drugs, such as angiotensin converting en-
zyme inhibitors (ACEi), hydralazine, and b-adrenergic
blocking agents, may be prescribed for treatment of cardiac
disease. We therefore conducted a post-hoc analysis and
compared BP and mortality in patients receiving ACEi with
patients receiving other antihypertensive medications.
There were no statistically significant differences in the
relationships between BP and mortality in the two groups.
It is possible that the protection conveyed by antihyperten-
sive therapy may be due to direct effects on sympathetic
function [42], atherosclerosis [43], and cardiac structure
and hemodynamics [4]. Alternatively, the use of antihyper-
tensive medications may be a marker for better overall
health care, or an indicator of the quality of care received
prior to the onset of ESRD.
The present study demonstrates an association between
low DBP and increased mortality. This finding is supported
by several [26, 31], but not all [44, 45], studies in patients
with treated essential hypertension. A recent meta-analysis
of seven clinical trials revealed that the highest event rate
for coronary heart disease was associated with the lowest
DBP [26]. The Hypertension Detection and Follow-up
Program (HDFP) reported that a minimum mortality rate
was obtained when DBP was reduced 26 mm Hg in the
whole group under study and 10 mm Hg in the stratum with
a baseline DBP of 90 to 104 mm Hg [31]. However, we
observed increased mortality in hemodialysis patients with
a low SBP. Only when post-dialysis SBP was treated as a
time-varying covariate were we able to show a relationship
between systolic hypertension and increased mortality in
patients with a SBP $ 180 mm Hg. In contrast, the Systolic
Hypertension in the Elderly Program demonstrated a 27%
reduction in the risk for myocardial infarction when SBP
was reduced from 171 to 142 mm Hg [9].
Our study has several limitations. First, we had limited
information on comorbidities. It was not until 1995 that
HCFA required a comorbidities data entry for ESRD
patients. The limited comorbidity data impairs our ability
to infer cause and effect relationships from our findings. A
second major limitation is that because serial echocardiog-
raphy was not performed routinely, we are not certain
whether low BP observed in some patients was due to a low
cardiac output or to a decrease in peripheral resistance.
Third, the information on the indications for antihyperten-
sive medications was limited.
In summary, our study demonstrates a “U” curve rela-
tionship between BP and mortality in a large sample of HD
patients. The Hypertension Optimal Treatment (HOT)
Study, an ongoing international, randomized multi-center
study, may provide conclusive evidence concerning the “J”
or “U” curve phenomenon in patients with essential hyper-
tension [46]. The association between low BP and increased
mortality observed in our study may merely reflect ante-
cedent cardiac disease and/or poor overall health status.
Severe hypertension (SBP $ 180 mm Hg) post-dialysis was
associated with increased mortality when treated as a
time-varying covariate in our study. However, we recognize
that neither pre- nor post-dialysis BP may correlate well
with MAP determined by ambulatory blood pressure mon-
itoring (ABPM) over a 48-hour period [47]. Other studies
[48, 49], excluding the study by Rodby, Vonesh and Korbet
[47] suggest that HD patients may lack a normal diurnal
variation in BP. Establishing optimal BP targets in HD
patients will require a multi-center, randomized, controlled
clinical trial that includes serial cardiac echocardiography,
48-hour ABPM, and information on antihypertensive med-
ications.
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APPENDIX
Abbreviations used in this article are: ABPM, ambulatory blood pres-
sure measurement; ACEi, angiotensin converting enzyme inhibitors; BP,
blood pressure; CV, cardiovascular and cerebrovascular; DBP, diastolic
blood pressure; DBP-pre or -post, pre-dialysis or post-dialysis diastolic
blood pressure; DCI, Dialysis Clinics, Inc.; EPO, erythropoietin; ESRD,
end-stage renal disease; HD, hemodialysis; HDFP, Hypertension Detec-
tion and Follow-up Program; HOT, Hypertension Optimal Treatment
Study; JNC V, Fifth Joint National Committee Report on Detection,
Evaluation and Treatment of High Blood Pressure; Kt/V, dialysis dose;
MAP, mean arterial pressure; RR, relative death rate; SPB, systolic blood
pressure; SBP-pre or -post, pre-dialysis or post-dialysis systolic blood
pressure.
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